Pune based Brandessence Market Research and Consulting released a report in December 2020 that valued the global 3D printed Drugs Market of US$ 272.17million in 2018 and forecast it reach US$ 437.04 million by 2025 with a CAGR of 7.0 % over the seven year period. The report says there is an increase in demand for fast soluble drugs which can disperse easily in the mouth and that this is the key factor that drives growth in the global 3D printed drugs market.
3D printed drugs are medications, which are designed by 3D printing technique to modify for individuals in a safe and effective way. Developed by using powder-liquid three dimensional printing technologies, this technique uses an aqueous fluid which is able to bind different or similar layer of powders and produces multiple types of products. Additionally, 3D printed drugs are able to liquefy unsolvable compounds such as silver chloride very easily.
The main objective and one of the major benefits of 3D printed drugs is how they will be able to be constructed with an individual’s specific requirements in mind, and even created in line with certain preferences. Factors like the size, dose, appearance and rate of delivery of a drug can be controlled. So, during the study of 3D printed drugs market, the researchers say they have considered 3D printed drugs and therapy to analyze the market.
Scope of the 3D Printed Drugs Market Report
The Global 3D Printed Drugs Market report is segmented on the basis of drug, end users, applications and by regional and country level. For instance the end user global 3D printed drugs market is segmented into hospitals, clinics and research laboratories.
The regions covered are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of 3D Printed Drugs is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.
Some major key players for producing 3D printed drugs include 3D Printer Drug Machine, Aprecia Pharmaceuticals, Hewlett Packard Caribe, GlaxoSmithKline, FabRx, Cycle Pharmaceuticals and others. Apparently, larger pharma companies are investing in 3D printing drug technology and are expected to enter into this market in near future.
Additional reports cite the example of Merck, entering into a partnership with Additive Manufacturing Customized Machines (AMCM) to produce 3D-printed drugs. The aim is to reduce the time for development, simplify the drug manufacturing process and to reduce costs. The technology also hold promise for more flexible decentralized production of drugs in the future.
According to the report, North America dominates the 3D printed drugs market due to the scale of its pharmaceutical companies and healthcare infrastructure. However it also says that Asia Pacific countries like China and India are expected to record the highest growth in the 3D printed drugs market due to massive investments in both R&D and the pharmaceutical industry.